<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Maura F</submitter><funding>U.S. Department of Health &amp;amp; Human Services | NIH | National Cancer Institute</funding><funding>NCI NIH HHS</funding><pagination>3844</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11076575</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(1)</volume><pubmed_abstract>Multiple myeloma (MM) is a heterogeneous disease characterized by frequent MYC translocations. Sporadic MYC activation in the germinal center of genetically engineered Vk*MYC mice is sufficient to induce plasma cell tumors in which a variety of secondary mutations are spontaneously acquired and selected over time. Analysis of 119 Vk*MYC myeloma reveals recurrent copy number alterations, structural variations, chromothripsis, driver mutations, apolipoprotein B mRNA-editing enzyme, catalytic polypeptide (APOBEC) mutational activity, and a progressive decrease in immunoglobulin transcription that inversely correlates with proliferation. Moreover, we identify frequent insertional mutagenesis by endogenous retro-elements as a murine specific mechanism to activate NF-kB and IL6 signaling pathway</pubmed_abstract><journal>Nature communications</journal><pubmed_title>The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humans.</pubmed_title><pmcid>PMC11076575</pmcid><funding_grant_id>R01 CA234181</funding_grant_id><funding_grant_id>CA186781</funding_grant_id><funding_grant_id>U01 CA271410</funding_grant_id><funding_grant_id>U54 CA224018</funding_grant_id><funding_grant_id>P30 CA240139</funding_grant_id><funding_grant_id>RO1CA234181</funding_grant_id><funding_grant_id>P50 CA186781</funding_grant_id><funding_grant_id>U54CA224018</funding_grant_id><funding_grant_id>R01 CA272426</funding_grant_id><pubmed_authors>Du MT</pubmed_authors><pubmed_authors>Ziccheddu B</pubmed_authors><pubmed_authors>Landgren O</pubmed_authors><pubmed_authors>Tafoya Alvarado Y</pubmed_authors><pubmed_authors>Shi CX</pubmed_authors><pubmed_authors>Morgan GJ</pubmed_authors><pubmed_authors>Stein CK</pubmed_authors><pubmed_authors>Sharik ME</pubmed_authors><pubmed_authors>Braggio E</pubmed_authors><pubmed_authors>Zhu YX</pubmed_authors><pubmed_authors>Meermeier EW</pubmed_authors><pubmed_authors>Maura F</pubmed_authors><pubmed_authors>Chesi M</pubmed_authors><pubmed_authors>Coffey DG</pubmed_authors><pubmed_authors>Bergsagel PL</pubmed_authors></additional><is_claimable>false</is_claimable><name>The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humans.</name><description>Multiple myeloma (MM) is a heterogeneous disease characterized by frequent MYC translocations. Sporadic MYC activation in the germinal center of genetically engineered Vk*MYC mice is sufficient to induce plasma cell tumors in which a variety of secondary mutations are spontaneously acquired and selected over time. Analysis of 119 Vk*MYC myeloma reveals recurrent copy number alterations, structural variations, chromothripsis, driver mutations, apolipoprotein B mRNA-editing enzyme, catalytic polypeptide (APOBEC) mutational activity, and a progressive decrease in immunoglobulin transcription that inversely correlates with proliferation. Moreover, we identify frequent insertional mutagenesis by endogenous retro-elements as a murine specific mechanism to activate NF-kB and IL6 signaling pathway</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 May</publication><modification>2026-06-03T04:22:49.98Z</modification><creation>2026-04-24T03:10:02.059Z</creation></dates><accession>S-EPMC11076575</accession><cross_references><pubmed>38714690</pubmed><doi>10.1038/s41467-024-48091-w</doi></cross_references></HashMap>